<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Dialysis-related amyloidosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Dialysis-related amyloidosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Dialysis-related amyloidosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan Kay, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wajeh Y Qunibi, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Berns, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steve J Schwab, MD, FACP, FASN
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dialysis-related amyloidosis (DRA) is a disabling disease characterized by accumulation and tissue deposition of amyloid fibrils consisting of beta2-microglobulin (beta2-m) in the bone, periarticular structures, and viscera of patients with end-stage kidney disease [
         <a href="#rid1">
          1-8
         </a>
         ]. Beta2-m is a component of the major histocompatibility complex that is present on cell surfaces and is normally cleared by glomerular filtration, with subsequent reabsorption and catabolism in proximal tubules. Clearance declines in patients with reduced kidney function, which leads to plasma accumulation and slow tissue deposition.
        </p>
        <p>
         The prevalence of DRA in patients on hemodialysis has decreased with the use of high-flux biocompatible membranes, which provide better clearance of beta2-m and are less likely to induce reactive inflammation. (See
         <a class="local">
          'Epidemiology'
         </a>
         below.)
        </p>
        <p>
         However, even modern kidney replacement therapies can be associated with retention of beta2-m. An overview of DRA is presented in this topic review. Other bone diseases and other complications associated with kidney disease are discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">
          "Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">
          "Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">
          "Management of secondary hyperparathyroidism in adult patients on dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other forms of amyloidosis are also discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2270360182">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H2229491201">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The exact prevalence of DRA is unknown since biopsy, the definitive diagnostic test, is rarely performed [
         <a href="#rid9">
          9
         </a>
         ] (see
         <a class="local">
          'Diagnosis'
         </a>
         below). The tissue deposition of amyloid that is detected histologically occurs much earlier than any clinical or radiographic manifestation of the disease. A postmortem study found that the proportion of patients on hemodialysis who had joint amyloid deposition was 21, 33, 50, 90, and 100 percent in those with a dialysis duration of &lt;2 years, 2 to 4 years, 4 to 7 years, 7 to 13 years, and &gt;13 years, respectively [
         <a href="#rid10">
          10
         </a>
         ]. By comparison, another study reported that the proportion of patients on hemodialysis needing surgery for carpal tunnel syndrome (CTS; a surrogate for DRA) was 0, 50, and almost 100 percent in those with a dialysis duration of 5 years, 14 years, and 20 years, respectively [
         <a href="#rid2">
          2,11
         </a>
         ]. However, these data were largely obtained during periods when hemodialysis was performed with low-flux, cellulose-derived dialysis membranes that were impermeable to beta2-microglobulin (beta2-m).
        </p>
        <p>
         Globally, the prevalence of DRA declined as low-flux dialysis membranes were replaced by high-flux dialyzer membranes that have a higher clearance of beta2-m [
         <a href="#rid7">
          7
         </a>
         ]. As an example, in one study of over 200,000 patients on hemodialysis from Japan, the incidence of CTS declined by almost one-half between 1998 and 2010 [
         <a href="#rid12">
          12
         </a>
         ]. Another observational study of Japanese patients on hemodialysis reported that higher beta2-m clearance and lower serum beta2-m levels were associated with longer intervals from the start of dialysis to surgery for CTS [
         <a href="#rid13">
          13
         </a>
         ]. However, DRA remains relatively common, especially among older patients on long-term dialysis. In two studies of patients with a mean age &gt;60 years who were on hemodialysis for more than approximately 10 years, the prevalence of DRA ranged from 21 to 28 percent [
         <a href="#rid14">
          14-16
         </a>
         ].
        </p>
        <p>
         The incidence of DRA in patients on peritoneal dialysis is less clear. Some observations suggest that peritoneal dialysis is associated with a similar risk of developing DRA as with hemodialysis [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3401079680">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors for DRA include the following [
         <a href="#rid18">
          18,19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older age and increased dialysis vintage
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of low-flux dialysis membranes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of bioincompatible dialysis membrane
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of residual kidney function
        </p>
        <p>
        </p>
        <p>
         These risk factors are discussed below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Older age and dialysis vintage
         </strong>
         – Older age and increased dialysis vintage are closely associated with DRA [
         <a href="#rid19">
          19,20
         </a>
         ]. Virtually all studies have demonstrated increasing prevalence with time on dialysis [
         <a href="#rid2">
          2,7,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low-flux dialysis membrane
         </strong>
         – DRA is more common among patients who undergo low-flux dialysis compared with high-flux dialysis [
         <a href="#rid7">
          7,20-22
         </a>
         ]. This is suggested by the following studies:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One multicenter study that included 221 patients who were receiving hemodialysis for more than five years found that, among patients &gt;60 years of age at the start of dialysis, the likelihood of developing amyloid bone disease was five times higher with low-flux compared with high-flux membranes  (
         <a class="graphic graphic_figure graphicRef68848" href="/z/d/graphic/68848.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a retrospective study, clinically evident DRA was compared among 89 patients on hemodialysis for at least 10 years and treated exclusively with low-flux, bioincompatible cellulose membranes; low-flux, intermediately biocompatible polysulfone (PMMA) membranes; or high-flux, highly biocompatible polysulfone (AN69) membranes [
         <a href="#rid22">
          22
         </a>
         ]. Clinical symptoms of DRA were most pronounced in the low-flux, bioincompatible cellulose membrane group and least pronounced in the high-flux, highly biocompatible membrane group.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One report compared patients on dialysis treated with a polyamide high-flux membrane with those treated with low-flux dialyzers; those on the high-flux membrane had lower beta2-m concentrations [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A cross-sectional study of 147 patients who had been undergoing hemodialysis for &gt;10 years and had a confirmed diagnosis of CTS (which is one of the two most common manifestations of DRA) reported that the combined use of high-flux dialyzer membranes and ultrapure dialysis fluid resulted in delayed onset of CTS [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The mechanisms by which high-flux dialysis membranes decrease DRA include improved dialysis clearance of beta2-m [
         <a href="#rid24">
          24-29
         </a>
         ] and, possibly, better preservation of residual kidney function, which improves overall clearance [
         <a href="#rid15">
          15,30,31
         </a>
         ]. Clearance of beta2-m by low-flux dialysis membranes is poor because the molecular weight of beta2-m (11,800 Da) is greater than the cut-off level of the membrane porosity. The more permeable membranes have an intrinsically greater rate of convective transport (although diffusion is limited by the size of the beta2-m molecule) and also may bind beta2-m directly [
         <a href="#rid24">
          24-29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bioincompatible dialysis membrane
         </strong>
         – DRA appears to be more common among patients who are dialyzed using a bioincompatible dialysis membrane than among those who are dialyzed using a highly biocompatible membrane [
         <a href="#rid20">
          20,22,32
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In one study (cited above), in which DRA was compared among patients on dialysis who used low-flux, bioincompatible cellulose membranes and low-flux, intermediately biocompatible polysulfone (PMMA) membranes versus high-flux, highly biocompatible polysulfone (AN69) membranes, the biocompatibility of the dialysis membrane appeared to be an independent determinant of the risk for developing DRA [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a trial in which 159 new patients on hemodialysis were randomly assigned to either a low-flux biocompatible or low-flux bioincompatible membrane, plasma beta2-m levels rose over time in both groups but the increase above baseline was less among patients treated with biocompatible membranes compared with those treated with bioincompatible membranes (2.6 versus 11.1 mg/L) [
         <a href="#rid32">
          32
         </a>
         ]. This beneficial effect was independent of the influence of residual kidney function and increased progressively over time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, in some studies, the prevalence of DRA was not higher among patients treated with cuprophane hemodialysis membranes compared with those treated with AN69 membranes [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lack of residual kidney function
         </strong>
         – The loss of even a minimal degree of residual kidney function is sufficient to decrease clearance and catabolism of beta2-m, thereby promoting the development of DRA. In one study, the plasma beta2-m concentrations were twice as high in patients on hemodialysis with a glomerular filtration rate (GFR) &lt;1 mL/min than in those with a GFR of 4 to 5 mL/min [
         <a href="#rid35">
          35
         </a>
         ]. As noted above, some studies suggest that high-flux membranes or ultrapure dialysis fluid preserve residual kidney function better than low-flux cellulosic membranes and thereby facilitate better overall clearance of beta2-m [
         <a href="#rid15">
          15,30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H86586406">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast to fragments of immunoglobulin light chains in primary amyloidosis and serum amyloid A in secondary amyloidosis, the amyloid protein in DRA is composed primarily of beta2-microglobulin (beta2-m) [
         <a href="#rid2">
          2,36,37
         </a>
         ]. DRA occurs because of increased tissue deposition of beta2-m (due to reduced kidney clearance and, possibly, to increased production) in a uremic milieu that appears to favor amyloid formation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduced clearance of beta2-m
         </strong>
         – The major underlying cause of DRA is the inability of patients with end-stage kidney disease to adequately clear beta2-m, even with modern, high-flux hemodialysis and/or convective therapies. This is because continuous generation of beta2-m far exceeds its removal by these dialysis modalities. As an example, assuming steady beta2-m generation in a 70 kg anuric individual, net yearly beta2-m retention is 111, 97, 77, 53, and 51 grams with low-flux conventional hemodialysis, high-flux dialysis, short daily hemodialysis, nocturnal hemodialysis, and short daily hemofiltration, respectively [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In peritoneal dialysis, there is relatively small removal of beta2-m due to the overall slow rate of convective transport and dialysate flow rate, despite the peritoneal membrane being highly permeable to small proteins. In one study, clearance was significantly higher with high-flux hemodialysis versus peritoneal dialysis (29 versus 6 liters/week per 1.73 m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. However, residual kidney function is generally higher among patients undergoing peritoneal dialysis compared with hemodialysis; this may increase overall clearance of beta2-m. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increased production of beta2-m
         </strong>
         – In addition to decreased clearance of beta2-m, the dialysis procedure itself (particularly via exposure to bioincompatible membranes) may mildly stimulate intradialytic beta2-m production. This was suggested by in vitro experiments that demonstrated increased beta2-m production by cultured peripheral blood monocytes obtained from patients on hemodialysis after dialysis with a cuprophane membrane but not by monocytes from patients dialyzed with the more biocompatible, non-complement-activating polymethylmethacrylate membrane [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Two mechanisms may contribute to the bioincompatible membrane-induced stimulation of beta2-m synthesis: contact of the cells with the membrane and activation of late complement components [
         <a href="#rid38">
          38
         </a>
         ]. It is also possible that dialysate contaminated with endotoxin stimulates the release of beta2-m from leukocytes and monocytes [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, observational data suggest that intradialytic generation of beta2-m may not be a significant underlying factor in DRA [
         <a href="#rid40">
          40,41
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum levels of beta2-m are similar or higher in patients treated with peritoneal dialysis as with hemodialysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rarely, DRA has developed in patients who have never undergone hemodialysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Amyloid formation
         </strong>
         – Although sustained increase in serum beta2-m concentration is a prerequisite for the formation of beta2-m amyloid fibrils, the exact mechanism of amyloidogenesis in patients on dialysis remains unclear. Studies have shown that elevation of circulating beta2-m levels is not the only cause of DRA [
         <a href="#rid42">
          42
         </a>
         ], and other substances, such as glycosaminoglycans, proteoglycans, apolipoprotein E, and serum amyloid P component, may be involved with amyloidogenesis in patients on long-term dialysis [
         <a href="#rid43">
          43
         </a>
         ]. These molecules are thought to stabilize the amyloid fibrils and inhibit their depolymerization. Moreover, at a neutral pH, lysophospholipids and nonesterified fatty acids accelerate amyloid fibril formation from beta2-m monomer and extension of amyloid fibrils in vitro and may enhance the amyloid deposition in vivo [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Glycosylated beta2-m, a modified microglobulin resulting from the activity of 3-deoxyglucose, has been found in amyloid deposits as advanced glycation end products [
         <a href="#rid45">
          45
         </a>
         ]. Since 3-deoxyglucose is present at increased levels in the serum of patients with advanced chronic kidney disease, including those on dialysis [
         <a href="#rid46">
          46
         </a>
         ], the modification of beta2-m may occur more readily in kidney failure. In addition, clearance of glycosylated beta2-m by dialysis membranes is lower than that of native beta2-m [
         <a href="#rid47">
          47
         </a>
         ]. The presence of glycosylated beta2-m in amyloid deposits may further enhance the development of these lesions by both stimulating the secretion of cytokines and acting as a chemoattractant and an apoptosis-delaying agent for monocytes [
         <a href="#rid48">
          48-50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism of injury
         </strong>
         – The mechanisms by which beta2-m amyloid deposition causes tissue injury are incompletely understood. Reactive inflammation may play a role, as suggested by observations that beta2-m amyloid lesions are associated with a marked influx of activated macrophages expressing cytokines, such as interleukin-1, tumor necrosis factor-alpha, and transforming growth factor-beta [
         <a href="#rid51">
          51
         </a>
         ]. These macrophages appear to be unable to adequately phagocytose deposited beta2-m [
         <a href="#rid52">
          52
         </a>
         ]. Beta2-m also may cause bone destruction by directly stimulating formation of osteoclasts [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical sequalae of DRA are due to the tissue deposition of beta2-microglobulin (beta2-m) amyloid, particularly in bone, articular cartilage, synovium, muscle, tendons, and ligaments [
         <a href="#rid54">
          54-56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H607810">
         <span class="h2">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of DRA typically occur after a period of five years or longer on dialysis and are discussed below.
        </p>
        <p class="headingAnchor" id="H2050796594">
         <span class="h3">
          Shoulder pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Shoulder pain is one of the most common manifestations of DRA and is due to scapulohumeral periarthritis and rotator cuff infiltration by amyloid [
         <a href="#rid1">
          1-3,57
         </a>
         ]. The shoulder pain related to scapulohumeral periarthritis is usually bilateral and typically is localized to the anterolateral aspect. Abduction may elicit pain, and patients may have limited range of motion, which worsens when patients are in a supine position, particularly at night or when undergoing dialysis treatments. This pain often improves when the patient sits or stands up [
         <a href="#rid9">
          9,58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H37253944">
         <span class="h3">
          Carpal tunnel syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carpal tunnel syndrome (CTS) is another common manifestation of DRA [
         <a href="#rid1">
          1-3,57
         </a>
         ]. Numbness and dysesthesias in the distribution of the median nerve are caused by beta2-m amyloid deposition in the carpal tunnel. In more severe cases, motor involvement can lead to complaints of weakness or clumsiness when using the hands. (See
         <a class="medical medical_review" href="/z/d/html/5288.html" rel="external">
          "Carpal tunnel syndrome: Clinical manifestations and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         CTS symptoms are typically bilateral, but if unilateral, they tend to occur more commonly on the side of a functioning vascular dialysis access [
         <a href="#rid9">
          9,59
         </a>
         ]. Carpal tunnel symptoms may worsen during dialysis due in part to steal syndrome [
         <a href="#rid9">
          9,60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1876042327">
         <span class="h3">
          Trigger finger
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trigger-finger (flexor tenosynovitis) manifestations of DRA occur most frequently after the onset of CTS, and often involve multiple fingers [
         <a href="#rid61">
          61
         </a>
         ]. Catching or locking of fingers during flexion is caused by amyloid deposition along flexor tendons. In more severe cases, the finger(s) may become locked in flexion. (See
         <a class="medical medical_review" href="/z/d/html/7755.html" rel="external">
          "Trigger finger (stenosing flexor tenosynovitis)", section on 'Presentation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7755.html" rel="external">
          "Trigger finger (stenosing flexor tenosynovitis)", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3683920262">
         <span class="h3">
          Spinal pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may experience neck or back pain related to involvement of the spine by a destructive spondyloarthropathy [
         <a href="#rid62">
          62
         </a>
         ]. Neck pain due to cervical spine involvement is more common than back pain. When it occurs, back pain due to destructive spondyloarthropathy is usually in the lumbar region. Infrequently, in patients who have undergone dialysis for 20 years or longer, epidural deposition of beta2-m amyloid may compress the spinal cord, causing quadriparesis or quadriplegia [
         <a href="#rid63">
          63-66
         </a>
         ]
         <strong>
          .
         </strong>
        </p>
        <p class="headingAnchor" id="H741684116">
         <span class="h3">
          Bone fracture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may present with bone fractures sustained after minimal trauma (ie, pathologic fractures), particularly of the femoral neck, as a result of bone cysts [
         <a href="#rid67">
          67
         </a>
         ]. Bone cysts occur most commonly in the carpal bones but may also occur in the femoral neck, phalanges of the hands, humeral head, acetabulum, tibial plateau, and distal radius.
        </p>
        <p class="headingAnchor" id="H3240580704">
         <span class="h3">
          Other manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other clinical manifestations of DRA are uncommon, but those that do occur are most often related to the gastrointestinal tract [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal
         </strong>
         – Gastrointestinal bleeding, ischemic or infarcted bowel with perforation, and pseudo-obstruction with gastric or colonic dilation have all been described [
         <a href="#rid68">
          68-75
         </a>
         ]. Patients may exhibit macroglossia and describe difficulty swallowing or pain with swallowing [
         <a href="#rid76">
          76,77
         </a>
         ]. The colon is the most frequently involved site of the gastrointestinal tract, but other sites of beta2-m amyloid deposition include the tongue, esophagus, stomach, and small intestine [
         <a href="#rid78">
          78-81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac, pulmonary, and skin
         </strong>
         – Congestive heart failure and/or mitral regurgitation may occur due to cardiac deposition of beta2-m amyloid. Cardiac, pulmonary, and cutaneous involvement with DRA have been described infrequently [
         <a href="#rid57">
          57,68,76,82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H608715">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The shoulders and hands are the most common sites of abnormal physical examination findings in patients with DRA.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Shoulder findings
         </strong>
         – The shoulders of patients with significant scapulohumeral periarthritis appear hypertrophied because of deposition of amyloid between muscles and tendons of the rotator cuff ("shoulder pad sign")  (
         <a class="graphic graphic_picture graphicRef91549" href="/z/d/graphic/91549.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid83">
          83,84
         </a>
         ]. The coracoacromial ligament and bicipital tendon may be tender to palpation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hand findings
         </strong>
         – CTS is suggested by weakness and possibly atrophy of the muscles of the thenar eminence and by decreased sensation in the thumb and index, middle, and ring fingers. These sensory deficits typically spare the thenar eminence. (See
         <a class="medical medical_review" href="/z/d/html/5288.html" rel="external">
          "Carpal tunnel syndrome: Clinical manifestations and diagnosis", section on 'Examination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pathognomonic "guitar string" sign in the palm refers to prominent flexor tendons that are apparent upon full or partial extension of the fingers [
         <a href="#rid85">
          85
         </a>
         ]. The "guitar string" sign in a patient with either shoulder pain or evidence of CTS strongly suggests DRA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         "Amyloid hand" refers to CTS-associated atrophy of the thenar eminence in conjunction with trigger fingers that have progressed to irreducible flexion contractures  (
         <a class="graphic graphic_picture graphicRef91549" href="/z/d/graphic/91549.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid2">
          2,84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1770659333">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preferred radiographic studies for the evaluation DRA vary by clinical presentation and are detailed elsewhere in this topic review (see
         <a class="local">
          'Evaluation'
         </a>
         below). Characteristic imaging findings in patients with DRA are as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conventional radiography may reveal radiolucent lesions or bone cysts, typically in the hand and/or long bones, and frequently with thin sclerotic margins  (
         <a class="graphic graphic_diagnosticimage graphicRef85529" href="/z/d/graphic/85529.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef91550" href="/z/d/graphic/91550.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid2">
          2,7
         </a>
         ]. Bone lesions are often bilateral and are typically found at periarticular sites [
         <a href="#rid86">
          86,87
         </a>
         ]. The bone lesions tend to enlarge more rapidly than the brown tumors of hyperparathyroidism, which are now rare, and usually increase in number and size over time. Plain radiography of the spine also can demonstrate findings of destructive spondyloarthropathy: severe narrowing of intervertebral spaces, vertebral body erosions, and end-plate destruction with minimal osteophyte formation [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ultrasonography of the shoulder typically demonstrates increased rotator cuff thickness, deposits with increased echogenicity between the muscles and tendons of the rotator cuff, and a thickened synovial sheath of the long head of the biceps [
         <a href="#rid83">
          83,88-90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Computed tomography (CT) findings of destructive spondyloarthropathy are similar to those of conventional radiography, as described above, but CT better detects osseus erosion and small osteolytic areas, especially in cortical bone [
         <a href="#rid86">
          86,87
         </a>
         ]. CT also is superior to conventional radiography for delineating the extent and severity of destructive spondyloarthropathy [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Magnetic resonance imaging (MRI) shows intraosseous, periarticular, and soft-tissue lesions, typically with low signal intensity on both T1- and T2-weighted images [
         <a href="#rid86">
          86,87,91
         </a>
         ]. Like CT, MRI can detect bony lesions too small to be seen with plain radiographs. MRI of the shoulder can show supraspinatus and/or subscapularis tendon thickening [
         <a href="#rid92">
          92
         </a>
         ]. Bone lesions usually show moderate enhancement following the administration of gadolinium-based contrast; however, many centers still do not allow patients with end-stage kidney disease to receive even next-generation gadolinium-based contrast agents. (See
         <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">
          "Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Approach to preventing nephrogenic systemic fibrosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1955.html" rel="external">
          "Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H2003856226">
         <span class="h2">
          Evaluation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to suspect the diagnosis
         </strong>
         – DRA should be suspected in patients who have been on dialysis for five years or longer and develop characteristic clinical features, especially new-onset shoulder pain not associated with trauma, carpal tunnel syndrome (CTS), and/or trigger finger.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Perform a physical examination
         </strong>
         – Careful physical examination of the patient may suggest the diagnosis of DRA. (See
         <a class="local">
          'Physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obtain selected imaging studies
         </strong>
         – The preferred radiographic studies to evaluate suspected DRA depend on the clinical presentation:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Shoulder pain
         </strong>
         – We prefer ultrasound for the evaluation of scapulohumeral periarthritis. However, MRI without contrast enhancement also may be used, either for initial evaluation or for patients with equivocal ultrasound findings. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Carpal tunnel syndrome and trigger finger
         </strong>
         – Plain radiography of both hands, including the wrists, is the preferred imaging study for patients with CTS and/or trigger finger. CTS and trigger finger are generally diagnosed without imaging, and plain radiography does not detect amyloid deposition in the carpal tunnel or along flexor tendons. However, bone cysts observed on these plain radiographs suggest hand involvement by beta2-microglobulin (beta2-m) amyloid. (See
         <a class="local">
          'Carpal tunnel syndrome'
         </a>
         above and
         <a class="local">
          'Trigger finger'
         </a>
         above and
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with CTS and/or trigger finger who have no findings or equivocal findings on initial plain radiography of the hands, we repeat imaging studies in six months. Because DRA is characterized by multiple bone cysts that enlarge rapidly over time, repeat plain radiographs can be useful in establishing the diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Spinal pain
         </strong>
         – CT of the spine without contrast is the preferred imaging study to evaluate neck or back pain in patients who may have destructive spondyloarthropathy. Normal plain radiographs effectively rule out destructive spondyloarthropathy, but suggestive plain radiographs generally require follow-up with CT. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         MRI of the spine without contrast also may be useful as initial or supplemental imaging, especially in the following two settings:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Suspected spinal cord compression or nerve root impingement (see
         <a class="medical medical_review" href="/z/d/html/14149.html" rel="external">
          "Polyradiculopathy: Spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes", section on 'Spinal stenosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Suspected infectious discitis and/or vertebral osteomyelitis (see
         <a class="local">
          'Differential diagnosis'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pathologic fracture
         </strong>
         – Imaging studies typically obtained for the diagnosis of bone fracture in the general population, usually plain radiography but sometimes CT or MRI, are adequate to evaluate bone lesions characteristic of DRA. However, for patients with suspected DRA who have pathologic fractures in locations other than the spine (eg, the femoral neck), we also obtain plain radiographs of both hands to determine the presence or absence of bone cysts (see
         <a class="local">
          'Establishing the diagnosis'
         </a>
         below). Patients with pathologic spine fractures due to DRA do not need hand imaging since they typically have radiographic evidence of destructive spondyloarthropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic tests we do not use
         </strong>
         – The following tests are not useful in the evaluation of DRA:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abdominal fat pad aspiration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Measurement of serum beta2-m. Beta2-m levels are elevated among patients on dialysis in the absence of DRA [
         <a href="#rid93">
          93,94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Scintigraphy with radiolabeled beta2-m or serum amyloid P component [
         <a href="#rid95">
          95-98
         </a>
         ], and positron emission tomography with fluorodeoxyglucose (PET-FDG) [
         <a href="#rid99">
          99
         </a>
         ]. Scintigraphy is often unavailable and has not been consistently useful as the results depend upon which specific protein is radiolabeled. PET-FDG remains an investigational imaging modality.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1365797689">
         <span class="h2">
          Establishing the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         DRA is typically a clinical diagnosis based upon the presence of characteristic features in patients who have been on dialysis for an extended period. Tissue biopsy is generally not needed to diagnose DRA.
        </p>
        <p>
         Generally accepted or validated clinical criteria for the diagnosis of DRA do not exist. We make the diagnosis of DRA in patients who have been on dialysis for ≥5 years and who meet one or both of the following criteria (see
         <a class="local">
          'Evaluation'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least one typical clinical manifestation of DRA (ie, shoulder pain due to scapulohumeral periarthritis, CTS, trigger finger [flexor tenosynovitis], or spinal pain due to destructive spondyloarthropathy) in conjunction with its characteristic findings on imaging
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pathologic fracture accompanied by the presence of bone cyst(s) in the affected bone and, for patients with non-vertebral fracture, bone cysts in one or both hands
        </p>
        <p>
        </p>
        <p>
         Although rarely performed, biopsy is the definitive diagnostic test for beta2-m amyloidosis [
         <a href="#rid5">
          5
         </a>
         ]. The amyloid found in the bone cysts and synovial tissue is similar to other forms of amyloid in its staining properties, with Congo red, and in exhibiting apple-green birefringence under polarized light. In contrast to fragments of immunoglobulin light chains in primary amyloidosis and serum amyloid A in secondary amyloidosis, the amyloid protein in DRA is composed primarily of beta2-m [
         <a href="#rid2">
          2,36,37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis"
         </a>
         .)
        </p>
        <p>
         A group in Japan has proposed a clinical set of criteria for the diagnosis of DRA [
         <a href="#rid16">
          16
         </a>
         ]. However, this diagnostic schema has not been validated, and we believe some of the individual criteria lack adequate specificity.
        </p>
        <p class="headingAnchor" id="H1782462125">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other conditions besides beta2-m amyloidosis may cause shoulder pain, CTS, and/or back pain in patients with end-stage kidney disease, especially in those who have received dialysis treatment for less than five years:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Calcific periarthritis, caused by hydroxyapatite crystal deposition in periarticular tissue, may cause shoulder pain with associated soft tissue swelling, especially in the setting of elevated serum levels of calcium and/or phosphorus. The presence of radiopaque periarticular calcifications on plain radiographs differentiates calcific periarthritis from the shoulder periarthritis observed in beta2-m amyloidosis. (See
         <a class="medical medical_review" href="/z/d/html/17002.html" rel="external">
          "Basic calcium phosphate (BCP) crystal-associated calcific periarthritis (tendinopathy)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subacromial bursitis, bicipital tendinitis, and supraspinatus tendinitis may develop with overuse of the shoulder. These conditions often present with severe shoulder pain at rest that is exacerbated by movement of the affected shoulder and may awaken the individual from sleep. Reflex sympathetic dystrophy syndrome also may present with shoulder pain and limited motion, often associated with or followed by pain, swelling, and stiffness of the ipsilateral hand and wrist with signs and symptoms of vasomotor instability. However, in these conditions, the shoulder does not appear hypertrophied with the appearance of a "shoulder pad."
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="local">
          'Physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/229.html" rel="external">
          "Biceps tendinopathy and tendon rupture"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/229.html" rel="external">
          "Biceps tendinopathy and tendon rupture"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Septic arthritis of the shoulder, most commonly caused by
         <em>
          Staphylococcus aureus
         </em>
         in patients receiving hemodialysis, typically causes severe shoulder pain at rest or upon any shoulder movement. This must be diagnosed by shoulder arthrocentesis performed under fluoroscopic or ultrasound guidance with culture of the aspirated synovial fluid. (See
         <a class="medical medical_review" href="/z/d/html/7666.html" rel="external">
          "Septic arthritis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with chronic kidney disease and renal osteodystrophy may develop shoulder pain due to pathological humeral fractures, which can be diagnosed on plain radiographs. (See
         <a class="medical medical_review" href="/z/d/html/7239.html" rel="external">
          "Evaluation of renal osteodystrophy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The manifestations of CTS in patients with DRA are similar to those in patients without DRA. However, DRA-associated CTS is more often bilateral [
         <a href="#rid16">
          16
         </a>
         ] and is accompanied by the radiographic and/or physical examination findings of DRA. (See
         <a class="local">
          'Imaging'
         </a>
         above and
         <a class="local">
          'Physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shoulder pain and CTS may be associated with the underlying disease process that resulted in kidney failure [
         <a href="#rid100">
          100
         </a>
         ]. Examples include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diabetes mellitus can lead to diabetic cheiroarthropathy, manifest by scapulohumeral periarthritis and CTS with or without trigger finger. Diabetic cheiroarthropathy is accompanied by characteristic physical examination findings and lacks DRA-associated radiographic features. (See
         <a class="medical medical_review" href="/z/d/html/5126.html" rel="external">
          "Overview of the musculoskeletal complications of diabetes mellitus", section on 'Shoulder pain'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5126.html" rel="external">
          "Overview of the musculoskeletal complications of diabetes mellitus", section on 'Hand abnormalities'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Primary (AL) amyloidosis may result in shoulder periarthritis and CTS. This can be distinguished from beta2-m amyloidosis only by histologic identification of the amyloid subunit protein in tissue.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Systemic lupus erythematosus may lead to shoulder joint inflammation or avascular necrosis of the humeral head causing shoulder pain and also may lead to CTS from median nerve compression by wrist synovitis. Avascular necrosis has characteristic findings on imaging, and wrist synovitis is generally apparent on physical examination. (See
         <a class="medical medical_review" href="/z/d/html/122049.html" rel="external">
          "Clinical manifestations and diagnosis of osteonecrosis (avascular necrosis of bone)", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1820.html" rel="external">
          "Monoarthritis in adults: Etiology and evaluation", section on 'Physical examination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infectious discitis and/or vertebral osteomyelitis may share clinical and radiographic features with destructive spondyloarthropathy [
         <a href="#rid86">
          86
         </a>
         ]. Hemodialysis catheter–associated bacteremia is common and may result in spine infections unaccompanied by fever and/or elevated white blood cell count. MRI may be useful in such patients. In contrast to the lesions seen in destructive spondyloarthropathy, infected structures of the spine typically have increased signal intensity on T2-weighted images (see
         <a class="local">
          'Imaging'
         </a>
         above) [
         <a href="#rid86">
          86
         </a>
         ]. Biopsy may be necessary in patients with suspected vertebral osteomyelitis to establish a microbiologic and histologic diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/7663.html" rel="external">
          "Vertebral osteomyelitis and discitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no specific medical treatment for DRA. However, removal of significant amounts of beta2-microglobulin (beta2-m) may slow progression of the disease. Although this is best accomplished by kidney transplantation (see
         <a class="local">
          'Impact of transplantation'
         </a>
         below), changes to the dialysis prescription also can increase the removal of beta2-m.
        </p>
        <p class="headingAnchor" id="H2411721151">
         <span class="h2">
          Dialysis modification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to dialysis modification depends on dialysis modality.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodialysis
         </strong>
         – The effective removal of beta2-m by hemodialysis requires the use of newer and more permeable dialysis membranes since cellulose membranes such as cuprophane membranes are impermeable to beta2-m. Increasing the duration and/or frequency of dialysis also increases the clearance of beta2-m.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Optimize the dialysis membrane
         </strong>
         – For patients on hemodialysis who have DRA, we suggest a biocompatible, high-flux membrane. However, virtually all patients in the United States and other resource-abundant countries are already dialyzed against a biocompatible, high-flux membrane. This recommendation is consistent with 2003 Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines [
         <a href="#rid5">
          5
         </a>
         ]. Most [
         <a href="#rid7">
          7,15,20-22,24-31
         </a>
         ], but not all [
         <a href="#rid33">
          33,34,101
         </a>
         ] studies have found that beta2-m level is lower among patients dialyzed with biocompatible high-flux membranes. (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There is limited evidence that the use of super-flux membranes may improve beta2-m clearance even more than with high-flux membranes [
         <a href="#rid102">
          102
         </a>
         ]. However, there are insufficient data upon which to recommend their use.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intensify dialysis
         </strong>
         – For patients on hemodialysis who have DRA, we suggest increasing the duration and frequency of dialysis. However, the optimal dialysis prescription for patients with DRA is unknown. Because of the logistics of in-center hemodialysis, and because of the extensive treatment times preferred, nocturnal home hemodialysis is ideal for patients with DRA. An example of an intensified home dialysis regimen for a patient with DRA who uses a low dialysate flow machine (eg, NxStage) is six to eight hours, six days per week.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with DRA who are unable or unwilling to perform home hemodialysis, we increase the duration of in-center, thrice-weekly dialysis sessions and, ideally, we add a fourth weekly treatment as logistics permit. Nocturnal hemodialysis is the preferred in-center option because it allows for longer treatment times (eg, eight hours). If in-center nocturnal hemodialysis is unavailable, we maximize the duration of each daytime dialysis session; though for scheduling and staff reasons, treatment times longer than five hours are usually not feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         No high-quality data demonstrate that increased dialysis dose improves or slows the progression of DRA. However, dialysis duration and frequency are important determinants of beta2-m clearance, and increasing the weekly treatment time decreases beta2-m concentrations [
         <a href="#rid103">
          103
         </a>
         ]. Despite substantial clearance, there is still significant retention of beta2-m with conventional three-times-weekly high-flux hemodialysis [
         <a href="#rid7">
          7,40,104
         </a>
         ]. Compared with conventional hemodialysis (performed for four hours, three times per week), nocturnal hemodialysis (performed for eight hours, six nights per week, at low blood- and dialysate-flow rates) is associated with significantly higher clearances of beta2-m (585 versus 127 mg/week) and a greater reduction in plasma beta2-m concentrations (39 versus 21 percent) [
         <a href="#rid105">
          105
         </a>
         ]. Short daily hemodialysis also appears to be associated with enhanced middle-molecule removal compared with that observed with conventional hemodialysis. (See
         <a class="medical medical_review" href="/z/d/html/1898.html" rel="external">
          "Short daily hemodialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peritoneal dialysis
         </strong>
         – For patients on peritoneal dialysis who have DRA, we suggest switching to hemodialysis via an arteriovenous fistula or graft. Because of the high risk of serious infection associated with hemodialysis catheters, we do not switch patients on peritoneal dialysis to catheter-based hemodialysis. For patients with DRA who switch to hemodialysis, the preferred hemodialysis regimens are the same as above.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients on peritoneal dialysis who do not wish to switch to hemodialysis, we generally do not intensify peritoneal dialysis unless conventional measures of dialysis adequacy are below target (see
         <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">
          "Prescribing peritoneal dialysis"
         </a>
         ). Clearance of beta2-m in patients on peritoneal dialysis depends mainly upon residual kidney function; thus, increasing peritoneal dialysis dose would not be expected to result in meaningful increases in beta2-m removal [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         No high-quality data demonstrate that switching from peritoneal dialysis to hemodialysis improves or slows the progression of DRA. However, high-flux hemodialysis results in significantly higher clearance of beta2-m compared with peritoneal dialysis (29 versus 6 liters/week per 1.73 m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid10">
          10
         </a>
         ]. Although the peritoneal membrane is highly permeable to small proteins and has the highest biocompatibility, only a small amount of beta2-m is removed daily with peritoneal dialysis because of slow convective transport and dialysate flow rate. Studies examining dialysis modality and DRA have been limited by the shorter average life-time dialysis duration in patients on peritoneal dialysis and have reported conflicting results. Some studies suggested that the incidence of DRA is similar in patients on hemodialysis and those on peritoneal dialysis [
         <a href="#rid107">
          107
         </a>
         ], while others suggest that its incidence and progression are greater in patients on hemodialysis [
         <a href="#rid96">
          96,108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other modalities
         </strong>
         – We do not use hemodiafiltration solely for the treatment of DRA. Significant removal of beta2-m occurs with hemofiltration and hemodiafiltration, although plasma beta2-m levels remain high with these modalities [
         <a href="#rid109">
          109-113
         </a>
         ]. Some [
         <a href="#rid114">
          114-116
         </a>
         ], though not all [
         <a href="#rid117">
          117
         </a>
         ], studies have suggested that the development of clinically significant carpal tunnel syndrome (CTS) occurs less frequently in patients treated with hemodiafiltration and hemofiltration. However, the role of these modalities for the prevention and/or treatment of DRA will remain unclear until more data are available.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H113723272">
         <span class="h2">
          Symptom management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Apart from enhancing beta2-m clearance by dialysis or kidney transplantation, treatment of DRA is otherwise palliative. Symptoms of DRA are managed by analgesics, which help to reduce periarticular and bone pain, and by surgery.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pain control
         </strong>
         – Our approach to chronic pain in patients on dialysis is detailed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/93774.html" rel="external">
          "Management of chronic pain in advanced chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgery
         </strong>
         – Because DRA may affect surgical management, clinicians referring a patient for surgical evaluation should communicate the diagnosis of DRA directly to the surgical team. Based upon clinical experience, we believe that the following surgical interventions and/or approaches may be beneficial for symptom control:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Arthroscopic or open surgery of the shoulder with removal of synovium infiltrated by amyloid often provides dramatic pain relief [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Early surgical correction of CTS is warranted since DRA is a progressive disease [
         <a href="#rid119">
          119
         </a>
         ]. For patients with DRA, carpal tunnel surgery should include debridement of the hypertrophied synovium that is infiltrated by beta2-m amyloid, rather than just transection of the transverse carpal ligament, to relieve median nerve compression more effectively. However, despite surgery, CTS typically recurs within two years and requires multiple repeat surgical decompression procedures over time [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Curettage and bone grafting of amyloid cysts in the femoral neck have been successful in relieving hip pain [
         <a href="#rid120">
          120
         </a>
         ] and may prevent pathologic fractures. The grafts were successfully incorporated into the bone defects.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Replacement of a diseased joint with a prosthesis must be considered on an individual basis; when performed, this modality can relieve pain and restore lost mobility [
         <a href="#rid9">
          9
         </a>
         ]. Pathologic fractures of the femoral neck, occurring in bone compromised by beta2-m amyloid deposition, should be treated with total joint arthroplasty, rather than by internal fixation, because of the poor quality of the bone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         No high-quality data have compared the outcomes of surgical procedures to treat DRA-related symptoms with outcomes of the same procedures in patients without DRA.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2258477281">
         <span class="h2">
          Other therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of beta2-m adsorption columns in the treatment of DRA remains undefined. Limited data suggest that beta2-m adsorption columns, which are used predominantly in Japan, are associated with increased beta2-m removal and better improvement in DRA symptoms compared with dialysis alone [
         <a href="#rid121">
          121-124
         </a>
         ]. A survey of 345 Japanese patients on dialysis reported that use of a beta2-m column was associated with improvement of DRA symptoms in over 85 percent of patients [
         <a href="#rid125">
          125
         </a>
         ]. Hypotension and anemia have limited use of this treatment in some patients. Although a beta2-m adsorption column has been approved by the FDA, it is rarely used in the United States.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          Doxycycline
         </a>
         has been shown to modulate the formation of beta2-m fibrils in vitro [
         <a href="#rid126">
          126
         </a>
         ]. However, in vivo data suggesting that doxycycline may ameliorate symptoms of DRA are limited to case reports [
         <a href="#rid127">
          127,128
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3155780531">
         <span class="h1">
          IMPACT OF TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney transplantation is considered the definitive therapy for DRA in patients with end-stage kidney disease. For patients who are undecided about whether to undergo a kidney transplant, DRA may provide incentive.
        </p>
        <p>
         Successful kidney transplantation reduces plasma beta2-m levels to normal, and joint pain usually resolves soon after the kidney allograft has begun to function [
         <a href="#rid5">
          5,129-132
         </a>
         ]. Over time, after transplantation, the amyloid deposits may also regress. In one study, articular amyloid deposition regressed in eight of nine patients with DRA, as detected by scanning with radiolabeled serum amyloid P component, approximately five years after successful kidney transplantation [
         <a href="#rid132">
          132
         </a>
         ]. By contrast, bone cysts resolve slowly after transplantation, and the destructive spondyloarthropathy may progress [
         <a href="#rid131">
          131-133
         </a>
         ]. DRA symptoms generally recur quickly in patients who restart dialysis after kidney graft failure [
         <a href="#rid131">
          131-133
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3841331194">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">
          "Society guideline links: Dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H287937375">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis and epidemiology
         </strong>
         – Among patients with end-stage kidney disease, dialysis-related amyloidosis (DRA) is a disorder caused by the inability to clear beta2-microglobulin (beta2-m), resulting in the deposition of beta2-m amyloid fibrils in bones, joints, and other soft tissues. The incidence of DRA now is much lower than had been reported previously, a trend that correlates with the increased use of high-flux biocompatible dialyzers with enhanced clearance of beta2-m. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The clinical manifestations of DRA typically occur after a period of five years or longer on dialysis and include the following (see
         <a class="local">
          'Clinical manifestations'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Shoulder pain due to scapulohumeral periarthritis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Carpal tunnel syndrome (CTS)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Trigger finger (flexor tenosynovitis)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Spinal pain due to destructive spondyloarthropathy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pathologic fractures due to rapidly enlarging bone cysts
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination and imaging
         </strong>
         – Shoulders and hands are the most common sites of abnormal physical examination findings in patients with DRA. Plain radiography often reveals bone cysts, especially near joints. Ultrasound, computed tomography, and magnetic resonance imaging (MRI) also may demonstrate characteristic findings. (See
         <a class="local">
          'Physical examination'
         </a>
         above and
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         –
         <strong>
         </strong>
         We make the diagnosis of DRA in patients who have been on dialysis for ≥5 years based upon the presence of typical clinical manifestations and characteristic imaging findings. Although tissue biopsy is generally not needed to diagnose DRA and is rarely performed, biopsy is the definitive diagnostic test for beta2-m amyloidosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – There is no specific medical treatment for DRA. However, removal of significant amounts of beta2-m by intensified, high-flux hemodialysis may prevent or slow progression of the disease. For patients with DRA, we modify dialysis and treat symptoms. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dialysis modification
         </strong>
         – Our approach to dialysis modification depends on dialysis modality.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Hemodialysis
         </strong>
         – For patients on hemodialysis who have DRA, we suggest a biocompatible, high-flux membrane rather than a bioincompatible or low-flux membrane (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, virtually all patients in the United States and other resource-abundant countries are already dialyzed against a biocompatible, high-flux membrane. For patients on hemodialysis who have DRA, we suggest increasing the duration and frequency of dialysis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Dialysis modification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Peritoneal dialysis
         </strong>
         – For patients on peritoneal dialysis who have DRA and who can undergo hemodialysis via an arteriovenous fistula or graft, we suggest switching to hemodialysis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Because of the high risk of serious infection associated with hemodialysis catheters, we do not switch patients on peritoneal dialysis to catheter-based hemodialysis. (See
         <a class="local">
          'Dialysis modification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptom management
         </strong>
         – Symptoms of DRA are managed in part by analgesics, which help to reduce periarticular and bone pain. A variety of surgeries also may improve DRA symptoms. Because DRA may affect surgical management, clinicians referring a patient for surgical evaluation should communicate the diagnosis of DRA directly to the surgical team. (See
         <a class="medical medical_review" href="/z/d/html/93774.html" rel="external">
          "Management of chronic pain in advanced chronic kidney disease"
         </a>
         and
         <a class="local">
          'Symptom management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of transplantation
         </strong>
         – Kidney transplantation is the definitive therapy for DRA in patients with end-stage kidney disease. Successful kidney transplantation reduces plasma beta2-m levels to normal, and joint pain usually resolves soon after the kidney allograft has begun to function. (See
         <a class="local">
          'Impact of transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4176981">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert E Cronin, MD, and William L Henrich, MD, MACP, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Fenves AZ, Emmett M, White MG, et al. Carpal tunnel syndrome with cystic bone lesions secondary to amyloidosis in chronic hemodialysis patients. Am J Kidney Dis 1986; 7:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch KM. Dialysis-related amyloidosis. Kidney Int 1992; 41:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gejyo F, Odani S, Yamada T, et al. Beta 2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 1986; 30:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C. Beta-2 microglobulin in renal disease. J Am Soc Nephrol 1998; 9:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winchester JF, Salsberg JA, Levin NW. Beta-2 microglobulin in ESRD: an in-depth review. Adv Ren Replace Ther 2003; 10:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dember LM, Jaber BL. Dialysis-related amyloidosis: late finding or hidden epidemic? Semin Dial 2006; 19:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrow B, Qunibi W. Specific bone and mineral disorders in patients with chronic kidney disease. Clinic Rev Bone Miner Metab 2012; 10:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay J. B2-microglobulin amyloidosis. Amyloid Int J Exp Clin Invest 1997; 4:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jadoul M, Garbar C, Noël H, et al. Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Kidney Int 1997; 51:1928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charra B, Calemard E, Laurent G. Chronic renal failure treatment duration and mode: their relevance to the late dialysis periarticular syndrome. Blood Purif 1988; 6:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoshino J, Yamagata K, Nishi S, et al. Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010. Nephrol Dial Transplant 2016; 31:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatano M, Kitajima I, Yamamoto S, et al. Dialysis-related carpal tunnel syndrome in the past 40 years. Clin Exp Nephrol 2022; 26:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tagami A, Tomita M, Adachi S, et al. Epidemiological survey and risk factor analysis of dialysis-related amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome. J Bone Miner Metab 2020; 38:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffl H. Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients. Hemodial Int 2014; 18:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishi S, Yamamoto S, Hoshino J, et al. The features of bone articular lesions in dialysis-related amyloidosis (DRA) and criteria for the clinical diagnosis of DRA. Ren Replace Ther 2019; 5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006; 70:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cianciolo G, Colí L, La Manna G, et al. Is beta2-microglobulin-related amyloidosis of hemodialysis patients a multifactorial disease? A new pathogenetic approach. Int J Artif Organs 2007; 30:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fry AC, Singh DK, Chandna SM, Farrington K. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif 2007; 25:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Ypersele de Strihou C, Jadoul M, Malghem J, et al. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991; 39:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Floege J, Koch KM. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes. Clin Nephrol 1994; 42 Suppl 1:S52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux. Nephrol Dial Transplant 2000; 15:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traut M, Haufe CC, Eismann U, et al. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study. Blood Purif 2007; 25:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zingraff J, Beyne P, Ureña P, et al. Influence of haemodialysis membranes on beta 2-microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 1988; 3:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaiser JP, Hagemann J, von Herrath D, Schaefer K. Different handling of beta 2-microglobulin during hemodialysis and hemofiltration. Nephron 1988; 48:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ullian ME, Hammond WS, Alfrey AC, et al. Beta-2-microglobulin-associated amyloidosis in chronic hemodialysis patients with carpal tunnel syndrome. Medicine (Baltimore) 1989; 68:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman M, Lagmiche M, Dhaene M, et al. Adsorption of beta 2-microglobulin on dialysis membranes: comparison of different dialyzers and effects of reuse procedures. Int J Artif Organs 1989; 12:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gejyo F, Narita I. Current clinical and pathogenetic understanding of beta2-m amyloidosis in long-term haemodialysis patients. Nephrology (Carlton) 2003; 8 Suppl:S45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997; 30:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17:1814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakim RM, Wingard RL, Husni L, et al. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996; 7:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler M, Netter P, Azoulay E, et al. Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy. Br J Rheumatol 1992; 31:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunner FP, Brynger H, Ehrich JH, et al. Case control study on dialysis arthropathy: the influence of two different dialysis membranes: data from the EDTA Registry. Nephrol Dial Transplant 1990; 5:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy JT, Williams AW, Johnson WJ. Serum beta 2-microglobulin concentration in dialysis patients: importance of intrinsic renal function. J Lab Clin Med 1994; 123:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorevic PD, Munoz PC, Casey TT, et al. Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis. Proc Natl Acad Sci U S A 1986; 83:7908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Ypersele De Strihou C, Jadoul M, Garbar C. Morphogenesis of joint beta 2-microglobulin amyloid deposits. Nephrol Dial Transplant 2001; 16 Suppl 4:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoels M, Jahn B, Hug F, et al. Stimulation of mononuclear cells by contact with cuprophan membranes: further increase of beta 2-microglobulin synthesis by activated late complement components. Am J Kidney Dis 1993; 21:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaoui PM, Stone WJ, Hakim RM. Effects of dialysis membranes on beta 2-microglobulin production and cellular expression. Kidney Int 1990; 38:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drüeke TB, Massy ZA. Beta2-microglobulin. Semin Dial 2009; 22:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morinière P, Marie A, el Esper N, et al. Destructive spondyloarthropathy with beta 2-microglobulin amyloid deposits in a uremic patient before chronic hemodialysis. Nephron 1991; 59:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gejyo F, Homma N, Suzuki Y, Arakawa M. Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 1986; 314:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto S, Kazama JJ, Narita I, et al. Recent progress in understanding dialysis-related amyloidosis. Bone 2009; 45 Suppl 1:S39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ookoshi T, Hasegawa K, Ohhashi Y, et al. Lysophospholipids induce the nucleation and extension of beta2-microglobulin-related amyloid fibrils at a neutral pH. Nephrol Dial Transplant 2008; 23:3247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niwa T, Katsuzaki T, Momoi T, et al. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 1996; 49:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niwa T. 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomed Sci Appl 1999; 731:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randoux C, Gillery P, Georges N, et al. Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes. Kidney Int 2001; 60:1571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyata T, Inagi R, Iida Y, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994; 93:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hou FF, Miyata T, Boyce J, et al. beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. Kidney Int 2001; 59:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hou FF, Jiang JP, Guo JQ, et al. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol 2002; 13:1296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuo K, Ikizler TA, Hoover RL, et al. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis. Kidney Int 2000; 57:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-García M, Argilés, Gouin-Charnet A, et al. Impaired lysosomal processing of beta2-microglobulin by infiltrating macrophages in dialysis amyloidosis. Kidney Int 1999; 55:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menaa C, Esser E, Sprague SM. Beta2-microglobulin stimulates osteoclast formation. Kidney Int 2008; 73:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Athanasou NA, Ayers D, Rainey AJ, et al. Joint and systemic distribution of dialysis amyloid. Q J Med 1991; 78:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noël LH, Zingraff J, Bardin T, et al. Tissue distribution of dialysis amyloidosis. Clin Nephrol 1987; 27:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakazawa R, Hamaguchi K, Hosaka E, et al. Synovial amyloidosis of beta 2-microglobulin type in patients undergoing long-term hemodialysis. Nephron 1986; 44:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sprague SM, Moe SM. Clinical manifestations and pathogenesis of dialysis-related amyloidosis. Semin Dial 1996; 9:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurent G, Calemard E, Charra B. Dialysis related amyloidosis. Kidney Int Suppl 1988; 24:S32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert MS, Robinson A, Baez A, et al. Carpal tunnel syndrome in patients who are receiving long-term renal hemodialysis. J Bone Joint Surg Am 1988; 70:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenzora JE. Dialysis carpal tunnel syndrome. Orthopedics 1978; 1:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portales-Castillo I, Yee J, Tanaka H, Fenves AZ. Beta-2 Microglobulin Amyloidosis: Past, Present, and Future. Kidney360 2020; 1:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orzincolo C, Bedani PL, Scutellari PN, et al. Destructive spondyloarthropathy and radiographic follow-up in hemodialysis patients. Skeletal Radiol 1990; 19:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allard JC, Artze ME, Porter G, et al. Fatal destructive cervical spondyloarthropathy in two patients on long-term dialysis. Am J Kidney Dis 1992; 19:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcelli C, Pérennou D, Cyteval C, et al. Amyloidosis-related cauda equina compression in long-term hemodialysis patients. Three case reports. Spine (Phila Pa 1976) 1996; 21:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allain TJ, Stevens PE, Bridges LR, Phillips ME. Dialysis myelopathy: quadriparesis due to extradural amyloid of beta 2 microglobulin origin. Br Med J (Clin Res Ed) 1988; 296:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez R, Praga M, Rivas Salas JJ, et al. Compressive myelopathy due to dialysis-associated amyloidosis. Nephron 1993; 65:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campistol JM, Solé M, Muñoz-Gómez J, et al. Pathological fractures in patients who have amyloidosis associated with dialysis. A report of five cases. J Bone Joint Surg Am 1990; 72:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou H, Pfeifer U, Linke R. Generalized amyloidosis from beta 2-microglobulin, with caecal perforation after long-term haemodialysis. Virchows Arch A Pathol Anat Histopathol 1991; 419:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinoda T, Komatsu M, Aizawa T, et al. Intestinal pseudo-obstruction due to dialysis amyloidosis. Clin Nephrol 1989; 32:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gal R, Korzets A, Schwartz A, et al. Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Report of seven cases and review of the literature. Arch Pathol Lab Med 1994; 118:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi HS, Heller D, Picken MM, et al. Infarction of intestine with massive amyloid deposition in two patients on long-term hemodialysis. Gastroenterology 1989; 96:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picken MM, Shen S. beta 2-Microglobulin amyloidosis: illustrative cases. Ultrastruct Pathol 1994; 18:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu TH, Tsai CY, Chiang SS, et al. Dialysis-related amyloidosis and acquired renal cystic disease with renal cell carcinoma in uremia. Nephron 1994; 67:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borczuk A, Mannion C, Dickson D, Alt E. Intestinal pseudo-obstruction and ischemia secondary to both beta 2-microglobulin and serum A amyloid deposition. Mod Pathol 1995; 8:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Mulder P, Cokelaere K, Terryn W. Chronic intestinal pseudo-obstruction due to β2microglobulin-amyloidosis in a patient on high-flux haemodialysis. BMJ Case Rep 2020; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi D, Hutchison AJ, Cary NR, et al. Macroglossia and amyloidoma of the buttock: evidence of systemic involvement in dialysis amyloid. Nephron 1990; 55:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guccion JG, Redman RS, Winne CE. Hemodialysis-associated amyloidosis presenting as lingual nodules. Oral Surg Oral Med Oral Pathol 1989; 68:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jimenez RE, Price DA, Pinkus GS, et al. Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. Am J Surg Pathol 1998; 22:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikegaya N, Kobayashi S, Hishida A, et al. Colonic dilatation due to dialysis-related amyloidosis. Am J Kidney Dis 1995; 25:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi S, Morita T, Koda Y, et al. Gastrointestinal involvement of dialysis-related amyloidosis. Clin Nephrol 1988; 30:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dulgheru EC, Balos LL, Baer AN. Gastrointestinal complications of beta2-microglobulin amyloidosis: a case report and review of the literature. Arthritis Rheum 2005; 53:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Floege J, Brandis A, Nonnast-Daniel B, et al. Subcutaneous amyloid-tumor of beta-2-microglobulin origin in a long-term hemodialysis patient. Nephron 1989; 53:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay J, Benson CB, Lester S, et al. Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum 1992; 35:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chattopadhyay C, Ackrill P, Clague RB. The shoulder pain syndrome and soft-tissue abnormalities in patients on long-term haemodialysis. Br J Rheumatol 1987; 26:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gravallese EM, Baker N, Lester S, et al. Musculoskeletal manifestations in beta 2-microglobulin amyloidosis. Case discussion. Arthritis Rheum 1992; 35:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiss E, Keusch G, Zanetti M, et al. Dialysis-related amyloidosis revisited. AJR Am J Roentgenol 2005; 185:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theodorou DJ, Theodorou SJ, Resnick D. Imaging in dialysis spondyloarthropathy. Semin Dial 2002; 15:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardinal E, Buckwalter KA, Braunstein EM, et al. Amyloidosis of the shoulder in patients on chronic hemodialysis: sonographic findings. AJR Am J Roentgenol 1996; 166:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sommer R, Valen GJ, Ori Y, et al. Sonographic features of dialysis-related amyloidosis of the shoulder. J Ultrasound Med 2000; 19:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jadoul M, Malghem J, Vande Berg B, van Ypersele de Strihou C. Ultrasonographic detection of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: a cross-sectional and longitudinal study. Nephrol Dial Transplant 1993; 8:1104.
          </a>
         </li>
         <li class="breakAll">
          Stone WJ. Beta2-microglobulin-associated amyloidosis of end-stage renal disease. In: Principles and Practice of Dialysis, 3rd ed, Henrich WL (Ed), Lippincott, Williams &amp; Wilkins, Philadelphia 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slavotinek JP, Coates PT, McDonald SP, et al. Shoulder appearances at MR imaging in long-term dialysis recipients. Radiology 2000; 217:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maury CP. beta 2-Microglobulin amyloidosis. A systemic amyloid disease affecting primarily synovium and bone in long-term dialysis patients. Rheumatol Int 1990; 10:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazama JJ, Yamamoto S, Takahashi N, et al. Abeta-2M-amyloidosis and related bone diseases. J Bone Miner Metab 2006; 24:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Floege J, Schäffer J, Ehlerding G. Beta 2-microglobulin-derived amyloidosis: clinical use of scintigraphy and insights into its pathogenesis. Nephrol Dial Transplant 1993; 8:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan SY, Baillod R, Brown E, et al. Clinical, radiological and serum amyloid P component scintigraphic features of beta2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1999; 14:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schäffer J, Burchert W, Floege J, et al. Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients. Kidney Int 2000; 58:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson SR, Hawkins PN, Richardson S, et al. Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet 1991; 338:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santagati G, Cataldo E, Columbano V, et al. Positron Emission Tomography Can Support the Diagnosis of Dialysis-Related Amyloidosis. J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kay J. Shoulder pain in the dialysis patient. Semin Dial 1995; 2:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz RJ, Washburn S, Cauble L, et al. The effect of dialyzer reprocessing on performance and beta 2-microglobulin removal using polysulfone membranes. Am J Kidney Dis 1993; 21:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pellicano R, Polkinghorne KR, Kerr PG. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial. Am J Kidney Dis 2008; 52:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leypoldt JK. Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration. Semin Dial 2005; 18:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward RA, Greene T, Hartmann B, Samtleben W. Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 2006; 69:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raj DS, Ouwendyk M, Francoeur R, Pierratos A. beta(2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 2000; 15:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64:2238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benz RL, Siegfried JW, Teehan BP. Carpal tunnel syndrome in dialysis patients: comparison between continuous ambulatory peritoneal dialysis and hemodialysis populations. Am J Kidney Dis 1988; 11:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jadoul M, Noel H, van Ypersele de Strihou C. Beta 2-microglobulin amyloidosis in a patient treated exclusively by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1990; 15:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Ypersele de Strihou C, Honhon B, Vandenbroucke JM, et al. Dialysis amyloidosis. Adv Nephrol Necker Hosp 1988; 17:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lornoy W, Becaus I, Billiouw JM, et al. On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant 2000; 15 Suppl 1:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yavuz A, Tetta C, Ersoy FF, et al. Uremic toxins: a new focus on an old subject. Semin Dial 2005; 18:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canaud B, Assounga A, Kerr P, et al. Failure of a daily haemofiltration programme using a highly permeable membrane to return beta 2-microglobulin concentrations to normal in haemodialysis patients. Nephrol Dial Transplant 1992; 7:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penne EL, van der Weerd NC, Blankestijn PJ, et al. Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients. Clin J Am Soc Nephrol 2010; 5:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locatelli F, Marcelli D, Conte F, et al. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 1999; 55:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koda Y, Nishi S, Miyazaki S, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakai S, Iseki K, Tabei K, et al. Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis 2001; 38:S212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabindranath KS, Strippoli GF, Roderick P, et al. Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review. Am J Kidney Dis 2005; 45:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takenaka R, Fukatsu A, Matsuo S, et al. Surgical treatment of hemodialysis-related shoulder arthropathy. Clin Nephrol 1992; 38:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otsubo S, Kimata N, Okutsu I, et al. Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial Transplant 2009; 24:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naito M, Ogata K, Shiota E, Oyama M. Amyloid bone cysts of the femoral neck. Impending fractures treated by curettage and bone grafting. J Bone Joint Surg Br 1994; 76:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gejyo F, Kawaguchi Y, Hara S, et al. Arresting dialysis-related amyloidosis: a prospective multicenter controlled trial of direct hemoperfusion with a beta2-microglobulin adsorption column. Artif Organs 2004; 28:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abe T, Uchita K, Orita H, et al. Effect of beta(2)-microglobulin adsorption column on dialysis-related amyloidosis. Kidney Int 2003; 64:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutsuki H. beta(2)-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis. Biochim Biophys Acta 2005; 1753:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuragano T, Inoue T, Yoh K, et al. Effectiveness of β(2)-microglobulin adsorption column in treating dialysis-related amyloidosis: a multicenter study. Blood Purif 2011; 32:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gejyo F, Amano I, Ando T, et al. Survey of the effects of a column for adsorption of β2-microglobulin in patients with dialysis-related amyloidosis in Japan. Ther Apher Dial 2013; 17:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giorgetti S, Raimondi S, Pagano K, et al. Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem 2011; 286:2121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montagna G, Cazzulani B, Obici L, et al. Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid 2013; 20:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piccoli GB, Hachemi M, Molfino I, et al. Doxycycline treatment in dialysis related amyloidosis: discrepancy between antalgic effect and inflammation, studied with FDG-positron emission tomography: a case report. BMC Nephrol 2017; 18:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campistol JM. Dialysis-related amyloidosis after renal transplantation. Semin Dial 2001; 14:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mourad G, Argilés A. Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol 1996; 7:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan SY, Irish A, Winearls CG, et al. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 1996; 50:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jadoul M, Malghem J, Pirson Y, et al. Effect of renal transplantation on the radiological signs of dialysis amyloid osteoarthropathy. Clin Nephrol 1989; 32:194.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1983 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3946414" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Carpal tunnel syndrome with cystic bone lesions secondary to amyloidosis in chronic hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1614057" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Dialysis-related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3537446" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Beta 2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9727382" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Beta-2 microglobulin in renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14520607" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14681859" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Beta-2 microglobulin in ESRD: an in-depth review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16551286" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Dialysis-related amyloidosis: late finding or hidden epidemic?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Specific bone and mineral disorders in patients with chronic kidney disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : B2-microglobulin amyloidosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9186884" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3293615" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Chronic renal failure treatment duration and mode: their relevance to the late dialysis periarticular syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26206763" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34415463" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Dialysis-related carpal tunnel syndrome in the past 40 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31414282" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Epidemiological survey and risk factor analysis of dialysis-related amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23718290" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The features of bone articular lesions in dialysis-related amyloidosis (DRA) and criteria for the clinical diagnosis of DRA
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16820785" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17992647" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Is beta2-microglobulin-related amyloidosis of hemodialysis patients a multifactorial disease? A new pathogenetic approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17622712" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2067196" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7923985" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10831638" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17957097" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3140102" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Influence of haemodialysis membranes on beta 2-microglobulin kinetics: in vivo and in vitro studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3278243" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Different handling of beta 2-microglobulin during hemodialysis and hemofiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2646507" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Beta-2-microglobulin-associated amyloidosis in chronic hemodialysis patients with carpal tunnel syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2674020" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Adsorption of beta 2-microglobulin on dialysis membranes: comparison of different dialyzers and effects of reuse procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15012691" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Current clinical and pathogenetic understanding of beta2-m amyloidosis in long-term haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12490682" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effect of dialysis dose and membrane flux in maintenance hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9292565" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12270990" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8704114" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1540782" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2122319" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Case control study on dialysis arthropathy: the influence of two different dialysis membranes: data from the EDTA Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8144998" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Serum beta 2-microglobulin concentration in dialysis patients: importance of intrinsic renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3532124" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11402089" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Morphogenesis of joint beta 2-microglobulin amyloid deposits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8465819" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Stimulation of mononuclear cells by contact with cuprophan membranes: further increase of beta 2-microglobulin synthesis by activated late complement components.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2266681" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effects of dialysis membranes on beta 2-microglobulin production and cellular expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19708985" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Beta2-microglobulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1766508" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Destructive spondyloarthropathy with beta 2-microglobulin amyloid deposits in a uremic patient before chronic hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3080684" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19303954" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Recent progress in understanding dialysis-related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18467373" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Lysophospholipids induce the nucleation and extension of beta2-microglobulin-related amyloid fibrils at a neutral pH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8648931" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10491986" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11576375" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8113390" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11231354" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : beta(2)-Microglobulin modified with advanced glycation end products delays monocyte apoptosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11961018" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10652049" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10027926" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Impaired lysosomal processing of beta2-microglobulin by infiltrating macrophages in dialysis amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18368032" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Beta2-microglobulin stimulates osteoclast formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2047516" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Joint and systemic distribution of dialysis amyloid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3555909" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Tissue distribution of dialysis amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3540695" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Synovial amyloidosis of beta 2-microglobulin type in patients undergoing long-term hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clinical manifestations and pathogenesis of dialysis-related amyloidosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3163049" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Dialysis related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3417700" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Carpal tunnel syndrome in patients who are receiving long-term renal hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/724236" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Dialysis carpal tunnel syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35372889" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Beta-2 Microglobulin Amyloidosis: Past, Present, and Future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2255945" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Destructive spondyloarthropathy and radiographic follow-up in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1739088" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Fatal destructive cervical spondyloarthropathy in two patients on long-term dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8742217" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Amyloidosis-related cauda equina compression in long-term hemodialysis patients. Three case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3126960" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Dialysis myelopathy: quadriparesis due to extradural amyloid of beta 2 microglobulin origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8290001" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Compressive myelopathy due to dialysis-associated amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2324144" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Pathological fractures in patients who have amyloidosis associated with dialysis. A report of five cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1949616" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Generalized amyloidosis from beta 2-microglobulin, with caecal perforation after long-term haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2612073" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Intestinal pseudo-obstruction due to dialysis amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8024407" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Systemic distribution of beta 2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Report of seven cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2909422" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Infarction of intestine with massive amyloid deposition in two patients on long-term hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8191619" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : beta 2-Microglobulin amyloidosis: illustrative cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7993425" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Dialysis-related amyloidosis and acquired renal cystic disease with renal cell carcinoma in uremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7675780" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Intestinal pseudo-obstruction and ischemia secondary to both beta 2-microglobulin and serum A amyloid deposition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31980473" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Chronic intestinal pseudo-obstruction due toβ2microglobulin-amyloidosis in a patient on high-flux haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2196475" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Macroglossia and amyloidoma of the buttock: evidence of systemic involvement in dialysis amyloid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2682428" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Hemodialysis-associated amyloidosis presenting as lingual nodules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9630180" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7747737" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Colonic dilatation due to dialysis-related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3052956" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Gastrointestinal involvement of dialysis-related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15696571" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Gastrointestinal complications of beta2-microglobulin amyloidosis: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2674745" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Subcutaneous amyloid-tumor of beta-2-microglobulin origin in a long-term hemodialysis patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1642657" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3580713" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The shoulder pain syndrome and soft-tissue abnormalities in patients on long-term haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1575795" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Musculoskeletal manifestations in beta 2-microglobulin amyloidosis. Case discussion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16303998" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Dialysis-related amyloidosis revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12191028" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Imaging in dialysis spondyloarthropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8571867" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Amyloidosis of the shoulder in patients on chronic hemodialysis: sonographic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11065265" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Sonographic features of dialysis-related amyloidosis of the shoulder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8272224" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Ultrasonographic detection of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: a cross-sectional and longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8272224" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Ultrasonographic detection of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: a cross-sectional and longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11058657" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Shoulder appearances at MR imaging in long-term dialysis recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2191408" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : beta 2-Microglobulin amyloidosis. A systemic amyloid disease affecting primarily synovium and bone in long-term dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16502130" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Abeta-2M-amyloidosis and related bone diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8255509" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Beta 2-microglobulin-derived amyloidosis: clinical use of scintigraphy and insights into its pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10383009" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Clinical, radiological and serum amyloid P component scintigraphic features of beta2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10916113" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1677697" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31546847" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Positron Emission Tomography Can Support the Diagnosis of Dialysis-Related Amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Shoulder pain in the dialysis patient
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8465821" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The effect of dialyzer reprocessing on performance and beta 2-microglobulin removal using polysulfone membranes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18423807" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16191181" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Kinetics of beta2-microglobulin and phosphate during hemodialysis: effects of treatment frequency and duration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16395268" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10607768" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : beta(2)-microglobulin kinetics in nocturnal haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14633148" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3376931" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Carpal tunnel syndrome in dialysis patients: comparison between continuous ambulatory peritoneal dialysis and hemodialysis populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2403753" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Beta 2-microglobulin amyloidosis in a patient treated exclusively by continuous ambulatory peritoneal dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3124550" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Dialysis amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10737167" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15934967" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Uremic toxins: a new focus on an old subject.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1328940" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Failure of a daily haemofiltration programme using a highly permeable membrane to return beta 2-microglobulin concentrations to normal in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19965537" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9893138" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9328951" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11576958" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Outcomes of hemodiafiltration based on Japanese dialysis patient registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15754266" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1424310" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Surgical treatment of hemodialysis-related shoulder arthropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19096084" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7983120" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Amyloid bone cysts of the femoral neck. Impending fractures treated by curettage and bone grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15084199" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Arresting dialysis-related amyloidosis: a prospective multicenter controlled trial of direct hemoperfusion with a beta2-microglobulin adsorption column.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12969174" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Effect of beta(2)-microglobulin adsorption column on dialysis-related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16168723" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : beta(2)-Microglobulin-selective direct hemoperfusion column for the treatment of dialysis-related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21934303" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Effectiveness ofβ(2)-microglobulin adsorption column in treating dialysis-related amyloidosis: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23379492" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Survey of the effects of a column for adsorption ofβ2-microglobulin in patients with dialysis-related amyloidosis in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21068391" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23734692" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28874122" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Doxycycline treatment in dialysis related amyloidosis: discrepancy between antalgic effect and inflammation, studied with FDG-positron emission tomography: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11264775" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Dialysis-related amyloidosis after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7645531" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Treatment of amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8738817" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8807599" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2680195" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Effect of renal transplantation on the radiological signs of dialysis amyloid osteoarthropathy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
